Clinical management of metastatic colorectal cancer in the era of precision medicine
F Ciardiello, D Ciardiello, G Martini… - CA: a cancer journal …, 2022 - Wiley Online Library
Colorectal cancer (CRC) represents approximately 10% of all cancers and is the second
most common cause of cancer deaths. Initial clinical presentation as metastatic CRC …
most common cause of cancer deaths. Initial clinical presentation as metastatic CRC …
BRAF and MEK inhibitors: use and resistance in BRAF-mutated cancers
JN Sanchez, T Wang, MS Cohen - Drugs, 2018 - Springer
The mitogen activated protein kinase/extracellular signal-related kinase (MAPK/ERK)
signaling pathway serves an integral role in growth, proliferation, differentiation, migration …
signaling pathway serves an integral role in growth, proliferation, differentiation, migration …
Encorafenib Plus Cetuximab as a New Standard of Care for Previously Treated BRAF V600E–Mutant Metastatic Colorectal Cancer: Updated Survival Results and …
J Tabernero, A Grothey, E Van Cutsem… - Journal of Clinical …, 2021 - ascopubs.org
PURPOSE BEACON CRC evaluated encorafenib plus cetuximab with or without binimetinib
versus investigators' choice of irinotecan or FOLFIRI plus cetuximab in patients with BRAF …
versus investigators' choice of irinotecan or FOLFIRI plus cetuximab in patients with BRAF …
Colorectal cancer
E Dekker, PJ Tanis, JLA Vleugels, PM Kasi… - The Lancet, 2019 - thelancet.com
Several decades ago, colorectal cancer was infrequently diagnosed. Nowadays, it is the
world's fourth most deadly cancer with almost 900 000 deaths annually. Besides an ageing …
world's fourth most deadly cancer with almost 900 000 deaths annually. Besides an ageing …
Encorafenib, Binimetinib, and Cetuximab in BRAF V600E–Mutated Colorectal Cancer
Background Patients with metastatic colorectal cancer with the BRAF V600E mutation have
a poor prognosis, with a median overall survival of 4 to 6 months after failure of initial …
a poor prognosis, with a median overall survival of 4 to 6 months after failure of initial …
NCCN guidelines insights: colon cancer, version 2.2018
AB Benson, AP Venook, MM Al-Hawary… - Journal of the National …, 2018 - jnccn.org
The NCCN Guidelines for Colon Cancer provide recommendations regarding diagnosis,
pathologic staging, surgical management, perioperative treatment, surveillance …
pathologic staging, surgical management, perioperative treatment, surveillance …
Vertical Pathway Inhibition Overcomes Adaptive Feedback Resistance to KRASG12C Inhibition
MB Ryan, F Fece de la Cruz, S Phat, DT Myers… - Clinical cancer …, 2020 - AACR
Purpose: Although KRAS represents the most commonly mutated oncogene, it has long
been considered an “undruggable” target. Novel covalent inhibitors selective for the …
been considered an “undruggable” target. Novel covalent inhibitors selective for the …
NCCN guidelines insights: rectal cancer, version 6.2020: featured updates to the NCCN guidelines
AB Benson, AP Venook, MM Al-Hawary… - Journal of the National …, 2020 - jnccn.org
The NCCN Guidelines for Rectal Cancer provide recommendations for the diagnosis,
evaluation, treatment, and follow-up of patients with rectal cancer. These NCCN Guidelines …
evaluation, treatment, and follow-up of patients with rectal cancer. These NCCN Guidelines …
Combined BRAF, EGFR, and MEK Inhibition in Patients with BRAFV600E-Mutant Colorectal Cancer
RB Corcoran, T André, CE Atreya, JHM Schellens… - Cancer discovery, 2018 - AACR
Although BRAF inhibitor monotherapy yields response rates> 50% in BRAF V600-mutant
melanoma, only approximately 5% of patients with BRAF V600E colorectal cancer respond …
melanoma, only approximately 5% of patients with BRAF V600E colorectal cancer respond …
Colon cancer, version 1.2017, NCCN clinical practice guidelines in oncology
AB Benson, AP Venook, L Cederquist, E Chan… - Journal of the National …, 2017 - jnccn.org
This portion of the NCCN Guidelines for Colon Cancer focuses on the use of systemic
therapy in metastatic disease. Considerations for treatment selection among 32 different …
therapy in metastatic disease. Considerations for treatment selection among 32 different …